AngioDynamics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AngioDynamics, Inc. on May 9, 2008, regarding the consummation of the acquisition of Oncobionic, Inc. The transaction closed following the successful initial use of Oncobionic's irreversible electroporation technology in a human clinical trial for soft tissue treatment conducted in early April 2008.
Key Financial Metrics
The filing details the financial terms of the acquisition but does not provide the Company's consolidated revenue, profit, cash flow, or margin data for the reporting period.
- Total Purchase Price: $25.4 million
- Assumed Liabilities: Approximately $400,000
- Payment Schedule:
- $5.0 million deposit paid in October 2006
- $10.0 million paid at closing on May 9, 2008
- $5.0 million due in November 2008
- $5.0 million due in November 2009
Material Changes
The primary material change is the addition of Oncobionic, Inc. as a subsidiary. The acquisition was contingent upon the successful clinical trial mentioned above, which served as the closing condition.
Outlook, Risks, and Contingencies
The filing includes standard forward-looking statements regarding future performance, strategies, and financial results. Management cautions that actual results may differ materially due to various risks, including:
- Regulatory approvals from the FDA and other agencies.
- Results of pending or future clinical trials.
- Patent litigation outcomes.
- Market acceptance and competition.
- Economic conditions and healthcare reforms.
The Company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the status of the remaining $10 million in purchase price installments due in 2008 and 2009.
- Review the attached Press Release (Exhibit 99.1) for specific details on the clinical trial results.
- Monitor future filings for regulatory approval status of the irreversible electroporation technology.
- Check subsequent 10-Q or 10-K filings for the impact of this acquisition on consolidated financial statements.